Dabigatran Etexilate Mesylate
Brand name: Dabigatran Etexilate
Rank #211 of 500 drugs by total cost
$66.0M
Total Cost
220,652
Total Claims
$66.0M
Total Cost
5,505
Prescribers
$299
Cost per Claim
54,850
Beneficiaries
505,974
30-Day Fills
$12K
Avg Cost/Provider
40
Avg Claims/Provider
About Dabigatran Etexilate Mesylate
Dabigatran Etexilate Mesylate (sold as Dabigatran Etexilate) was prescribed 220,652 times by 5,505 Medicare Part D providers in 2023, costing the program $66.0M. At $299 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 208 | Abaloparatide (Tymlos) | $68.4M | 24,417 |
| 209 | Treprostinil Diolamine (Orenitram Er) | $68.2M | 5,964 |
| 210 | Esomeprazole Magnesium (Esomeprazole Magnesium) | $66.3M | 964,193 |
| 211 | Dabigatran Etexilate Mesylate (Dabigatran Etexilate) | $66.0M | 220,652 |
| 212 | Netarsudil Mesylate (Rhopressa) | $65.6M | 129,116 |
| 213 | Risperidone Microspheres (Risperdal Consta) | $64.8M | 47,567 |
| 214 | Venlafaxine Hcl (Venlafaxine Hcl) | $64.7M | 2,187,710 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology